Viking Therapeutics VKTX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -47.3%-29.4pp | -17.9%+16.9pp | -34.8%+4.9pp | -39.7%-15.0pp | |
| Return on invested capital | -59.2%-33.0pp | -26.3%+23.6pp | -49.9%-0.6pp | -49.2%-20.8pp | |
| Efficiency | |||||
| Asset turnover | 0×— | 0×— | 0×— | 0×— | |
| Liquidity | |||||
| Current ratio | 9.3×-23.8× | 33.1×+13.9× | 19.2×+11.6× | 7.6×-16.4× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $5.67-29.7% | $8.07+119% | $3.69+95.3% | $1.89-27.7% | |
| Valuation | |||||
| Market capitalization | $3.98B-11.3% | $4.48B+141% | $1.86B+158% | $720.87M+100% | |
| Price / book | 6.2×+1.1× | 5.1×-0.3× | 5.3×+0.4× | 5×+3.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Viking Therapeutics's ratios come from?
- Every ratio is computed from Viking Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.